415 related articles for article (PubMed ID: 33608812)
1. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
Min HY; Lee HY
Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
[TBL] [Abstract][Full Text] [Related]
2. Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC).
Umar H; Wahab HA; Attiq A; Amjad MW; Bukhari SNA; Ahmad W
Mutat Res; 2024; 828():111856. PubMed ID: 38520879
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
Bi YY; Chen Q; Yang MY; Xing L; Jiang HL
Nat Commun; 2024 Mar; 15(1):2759. PubMed ID: 38553451
[TBL] [Abstract][Full Text] [Related]
4. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
Chen X; Zeng C
Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.
Xiang Y; Liu X; Wang Y; Zheng D; Meng Q; Jiang L; Yang S; Zhang S; Zhang X; Liu Y; Wang B
Front Immunol; 2024; 15():1366260. PubMed ID: 38655260
[TBL] [Abstract][Full Text] [Related]
6. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
Middleton G; Crack LR; Popat S; Swanton C; Hollingsworth SJ; Buller R; Walker I; Carr TH; Wherton D; Billingham LJ
Ann Oncol; 2015 Dec; 26(12):2464-9. PubMed ID: 26410619
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages in non-small-cell lung cancer: From treatment resistance mechanisms to therapeutic targets.
Huang Z; Xiao Z; Yu L; Liu J; Yang Y; Ouyang W
Crit Rev Oncol Hematol; 2024 Apr; 196():104284. PubMed ID: 38311012
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms associated with chemoresistance in esophageal cancer.
Lohan-Codeço M; Barambo-Wagner ML; Nasciutti LE; Ribeiro Pinto LF; Meireles Da Costa N; Palumbo A
Cell Mol Life Sci; 2022 Feb; 79(2):116. PubMed ID: 35113247
[TBL] [Abstract][Full Text] [Related]
9. An emerging role of N-glycosylation in cancer chemoresistance.
Sun Y; Wu T; Gu J
Carbohydr Res; 2024 May; 539():109107. PubMed ID: 38613897
[TBL] [Abstract][Full Text] [Related]
10. Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer.
Costea T; Vlad OC; Miclea LC; Ganea C; Szöllősi J; Mocanu MM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936346
[TBL] [Abstract][Full Text] [Related]
11. Beyond Tissue Stiffness and Bioadhesivity: Advanced Biomaterials to Model Tumor Microenvironments and Drug Resistance.
Singh A; Brito I; Lammerding J
Trends Cancer; 2018 Apr; 4(4):281-291. PubMed ID: 29606313
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of tumor cell plasticity in modifying therapeutic response.
Qin S; Jiang J; Lu Y; Nice EC; Huang C; Zhang J; He W
Signal Transduct Target Ther; 2020 Oct; 5(1):228. PubMed ID: 33028808
[TBL] [Abstract][Full Text] [Related]
13. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.
Lwin Z; Riess JW; Gandara D
J Thorac Dis; 2013 Oct; 5 Suppl 5(Suppl 5):S556-64. PubMed ID: 24163748
[TBL] [Abstract][Full Text] [Related]
14. Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer:
Murphy DJ; Mayoral M; Larici AR; Ginsberg MS; Cicchetti G; Fintelmann FJ; Marom EM; Truong MT; Gill RR
AJR Am J Roentgenol; 2023 Oct; 221(4):409-424. PubMed ID: 37095669
[TBL] [Abstract][Full Text] [Related]
15. Improving targeted small molecule drugs to overcome chemotherapy resistance.
Rismanbaf A
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1945. PubMed ID: 37994401
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of calcium homeostasis in cancer and its role in chemoresistance.
Kumari N; Pullaguri N; Rath SN; Bajaj A; Sahu V; Ealla KKR
Cancer Drug Resist; 2024; 7():11. PubMed ID: 38510751
[TBL] [Abstract][Full Text] [Related]
17. Recurrent oral cancer: current and emerging therapeutic approaches.
da Silva SD; Hier M; Mlynarek A; Kowalski LP; Alaoui-Jamali MA
Front Pharmacol; 2012; 3():149. PubMed ID: 23060791
[TBL] [Abstract][Full Text] [Related]
18. Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth.
Lacy MS; Jenner AL
Bull Math Biol; 2024 Mar; 86(4):43. PubMed ID: 38502371
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance mechanisms in cancers: Execution of pro-survival strategies.
Dhanyamraju PK
J Biomed Res; 2024 Feb; 38(2):95-121. PubMed ID: 38413011
[TBL] [Abstract][Full Text] [Related]
20. Getting Lost in the Cell-Lysosomal Entrapment of Chemotherapeutics.
Zhai X; El Hiani Y
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33297435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
